Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7282502 CCR9 inhibitors and methods of use thereof

Patent 7282502 was granted and assigned to Millennium Pharmaceuticals on October, 2007 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

1

Patent attributes

Current Assignee

Millennium Pharmaceuticals

1

Patent Jurisdiction

United States Patent and Trademark Office

1

Patent Number

Patent Inventor Names

Chen Shaowu1

Geraldine C. B. Harriman1

Paul Fleming1

Zhan Shi1

Date of Patent

October 16, 2007

1

Patent Application Number

113916331

Date Filed

March 28, 2006

1

Patent Primary Examiner

Venkataraman Balasubramanian

1

Patent abstract

The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7282502 CCR9 inhibitors and methods of use thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.